Toinv

Another piece in the puzzle - not an easily discernable corner or side piece - not sure where to put this one yet but it will soon fall into place - could be the good old boy network - or a reward of sorts for trial implementation - or a front for a bigger deal - I believe it was you that posted earlier it's not a huge market - but Israel is well connected and highly visible - if the double blinded trial is meeting or exceeding established endpoints you can be sure some eyebrows are being raised - my cardio team at UofPenn hospital is world class and state of the art - Entresto is a new cardio drug(Novartis) that the FDA fast tracked in 2016 due to remarkable MACE reduction results in a PhaseIII trial- it is quickly becoming a standard of care pill for cardio patients with low ejection fraction - my cardio team highly recommended Entresto as a new therapy for me - the point being that enhancing RVX's visibility and profile is important and challenging - as DM mentioned in the December webcast - being a pioneer in epigenetics has it's disadvantages, namely, getting the word out - 4 papers published in 2017 with 5 more to come in 2018 extolling the benefits of BET inhibition - so many benefits with RVX - the renal studies are unbelievable - what did Hepalink know ~ three years ago when it paid 2.67 for RVX-208 rights in China, country with highest rate of CKD - my intuition tells me that we are close to critical mass - an ingenius way to spread the news and gain exposure before RVX gets gobbled up for chump change in a hostile takeover - keep the deals coming - just some late night musings - all my opinion of course - please dyodd 

Chicagoest